509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01M-J. Ahn, Isamu Okamoto, Nicolas Girard et al.|Annals of Oncology|2023Cited by 15
LBA7 Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05M-J. Ahn, Weili Gu, Jacob Sands et al.|Annals of Oncology|2024Cited by 9